Researchers led by Tulane University and Shenzhen Third People's Hospital have developed an enhanced CRISPR-based diagnostic assay, ActCRISPR-TB, designed for rapid, affordable tuberculosis (TB) detection. Utilizing non-sputum samples like cheek swabs and stool, the test operates at room temperature and delivers results within an hour. The one-pot recombinase polymerase amplification and CRISPR-Cas12a approach optimizes sensitivity and throughput, promising a scalable solution for community screening in resource-limited areas where traditional sputum samples are difficult to obtain.